Matches in Wikidata for { <http://www.wikidata.org/entity/Q82992297> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q82992297 description "article scientifique publié en 2010" @default.
- Q82992297 description "artículu científicu espublizáu n'avientu de 2010" @default.
- Q82992297 description "scientific article published on 21 December 2010" @default.
- Q82992297 description "wetenschappelijk artikel" @default.
- Q82992297 description "наукова стаття, опублікована в грудні 2010" @default.
- Q82992297 description "գիտական հոդված հրատարակված 2010 թվականի դեկտեմբերի 21-ին" @default.
- Q82992297 name "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 name "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 type Item @default.
- Q82992297 label "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 label "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 prefLabel "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 prefLabel "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 P1104 Q82992297-E52B6A79-41AA-4821-A775-05D66E51F3DC @default.
- Q82992297 P1433 Q82992297-A617679E-4E8D-40C5-A99F-6D9330419DCD @default.
- Q82992297 P1476 Q82992297-6D70C935-281C-4BC9-B76A-48C156DA32EF @default.
- Q82992297 P2093 Q82992297-2D49E391-D549-40F7-8856-A28707C73886 @default.
- Q82992297 P2093 Q82992297-2EBBE591-0EE6-4DAE-BEC3-0F3C143A109C @default.
- Q82992297 P2093 Q82992297-5F510E2F-7BC1-4B2F-99F6-2CF2DDB3578B @default.
- Q82992297 P2093 Q82992297-5FBDB118-D1F9-4B25-8BD1-EB572453CEE9 @default.
- Q82992297 P2093 Q82992297-6F39DE49-18F1-4892-86D0-44357E39E58A @default.
- Q82992297 P2093 Q82992297-784F337E-1C37-411D-85E2-F3A722C596CF @default.
- Q82992297 P2093 Q82992297-B2A92AAD-5FB2-4C35-95E0-E36BA19F8956 @default.
- Q82992297 P2093 Q82992297-BB69D5CC-B48D-4B33-8F90-45A54EF77059 @default.
- Q82992297 P2093 Q82992297-C04DF336-3FEC-40A2-B7BC-9AF10E2D3AF5 @default.
- Q82992297 P2093 Q82992297-C85321ED-3089-4281-A142-937391BD2C6C @default.
- Q82992297 P2093 Q82992297-D021C561-0AF9-4552-A9A7-9212A4BA882E @default.
- Q82992297 P2093 Q82992297-D64CE100-E4AA-443A-A991-DD95C6E1BA94 @default.
- Q82992297 P2093 Q82992297-DAD5E40F-820B-4C14-8981-2F6BFC264E9F @default.
- Q82992297 P2093 Q82992297-F7490FB7-EC03-491C-BEF9-9DCB8F9DDDB3 @default.
- Q82992297 P2093 Q82992297-F9538BB3-CFD0-4A64-9B1C-DA4D971618C6 @default.
- Q82992297 P304 Q82992297-8233FE0F-F52D-4E42-A3C2-57CE13F8455B @default.
- Q82992297 P31 Q82992297-E81B90AB-D47F-4F80-AC76-ACE7551985A0 @default.
- Q82992297 P356 Q82992297-057ACC84-4717-43EB-AD29-C69A565FB4E3 @default.
- Q82992297 P433 Q82992297-AE3F6147-208B-41F4-B6A8-0A40F5573A24 @default.
- Q82992297 P478 Q82992297-B93F087F-EFE2-43AD-BC2B-5F374B6361CF @default.
- Q82992297 P50 Q82992297-D5E24C8E-D4C1-4471-BD0C-0851B56E5DF8 @default.
- Q82992297 P577 Q82992297-E9207952-EDAC-420C-982F-6B2537C76960 @default.
- Q82992297 P698 Q82992297-A42414E0-CF99-4AE2-B457-8F35C6D248C6 @default.
- Q82992297 P356 BLOOD-2010-09-307280 @default.
- Q82992297 P698 21177436 @default.
- Q82992297 P1104 "+7" @default.
- Q82992297 P1433 Q885070 @default.
- Q82992297 P1476 "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity" @default.
- Q82992297 P2093 "Andrea Corbacioglu" @default.
- Q82992297 P2093 "Arnold Ganser" @default.
- Q82992297 P2093 "Bas J Wouters" @default.
- Q82992297 P2093 "Bob Löwenberg" @default.
- Q82992297 P2093 "Claudia A J Erpelinck" @default.
- Q82992297 P2093 "Frederik Damm" @default.
- Q82992297 P2093 "Hartmut Döhner" @default.
- Q82992297 P2093 "Jürgen Krauter" @default.
- Q82992297 P2093 "Konstanze Döhner" @default.
- Q82992297 P2093 "Lars Bullinger" @default.
- Q82992297 P2093 "Mathijs A Sanders" @default.
- Q82992297 P2093 "Peter J M Valk" @default.
- Q82992297 P2093 "Richard F Schlenk" @default.
- Q82992297 P2093 "Ruud Delwel" @default.
- Q82992297 P2093 "Sonja C van der Poel-van de Luytgaarde" @default.
- Q82992297 P304 "2469-2475" @default.
- Q82992297 P31 Q13442814 @default.
- Q82992297 P356 "10.1182/BLOOD-2010-09-307280" @default.
- Q82992297 P433 "8" @default.
- Q82992297 P478 "117" @default.
- Q82992297 P50 Q59680338 @default.
- Q82992297 P577 "2010-12-21T00:00:00Z" @default.
- Q82992297 P698 "21177436" @default.